5:48
Iron and inflammation in anemia and sickle cell disease
Francesca Vinchi
1:57
Biomarkers in lymphoma
Arjan Diepstra
3:42
Key factors in the tumor-tumor microenvironment relationship in myeloma
Bruno Paiva
5:35
Contemporary designs for multiple myeloma treatment
Gareth Morgan
1:56
Clinical trials investigating venetoclax combinations for AML
Andrew Wei
1:14
Understanding gene-gene interactions via machine learning: Pandora’s box?
Andrew Wei
2:24
The latest clinical trials into novel AML therapies
Eytan Stein
1:43
Biological rationales when determining AML therapies
Chrisoph Röllig
1:48
The challenges of choosing the right target antigen in AML compared to ALL
Marion Subklewe
2:38
Primary and secondary resistance in AML
Eytan Stein
1:38
Managing AML in elderly patients
Chrisoph Röllig
1:45
MRD detection techniques in AML: pros and cons
Chrisoph Röllig
1:37
Overcoming the issues with clinical trial recruitment
Arnold Ganser
2:28
Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser
1:41
Finding the right targets for CAR T-cell therapy in AML
Arnold Ganser
1:38
Challenges with the identification of ALL subtypes
Charles Mullighan
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals